NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,767.62 +255.93 (+1.55%) CRUDE OIL
83.02 +0.17 (+0.21%) GOLD FUTURES
2,316.10 -30.30 (-1.29%) DOW
38,239.98 +253.58 (+0.67%) Bitcoin GBP
54,036.55 +259.74 (+0.48%)
BeiGene, Ltd. (BGNE)
After hours:
| Previous close | 129.52 |
| Open | 130.55 |
| Bid | 130.50 x 100 |
| Ask | 131.60 x 100 |
| Day's range | 129.96 - 133.08 |
| 52-week range | 126.97 - 266.67 |
| Volume | |
| Avg. volume | 245,720 |
| Market cap | 14.548B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in t
- Business Wire
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 13, 2024--The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced that the first doses of BRUKINSA® (zanubrutinib) have been administered for the treatment of adult patients with chronic lympho
- Business Wire
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 07, 2024--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), in combination with the anti-CD20 monoclonal antibody obinutuzumab, after two or more lines of systemic therapy. The indication is
